Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Ginkgo Bioworks Holdings, Inc.
ISIN US37611X2099
|WKN A40KL9
Market cap (in EUR)
338 m
Country
United States
Sector
Healthcare
Overview
Description
Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 338 m |
| EPS, EUR | -5.04 |
| P/B ratio | 0.7 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 151 m |
| Net income, EUR | -277 m |
| Profit margin | -183.81% |
Articles les plus récents
Articles les plus consultés
— Les données utilisées sont mises à disposition par Trackinsight, etfinfo, Xignite Inc., gettex, FactSet et justETF GmbH. Les cotations sont des cotations en temps réel (gettex), des cotations boursières retardées de 15 minutes ou des VNI (quotidiennes publiées par le fournisseur du fonds). Par défaut, les rendements des ETF incluent les paiements de dividendes (le cas échéant). Aucune garantie n'est donnée quant à l'exhaustivité, la précision et l'exactitude des informations affichées.